Primatene mist
I read with interest the article by Ho et al,1 “Cost-effectiveness of budesonide-formoterol vs inhaled epinephrine in US adults with mild asthma.” How interesting to see a cost analysis of using this over-the-counter (OTC) treatment compared with guidelines-based treatment! I agree with the authors that using OTC inhaled epinephrine is not e vidence-based and can be dangerous, even deadly.1,2 Current asthma guidelines suggest using bronchodilator only in conjunction with inhaled corticosteroid.3 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - May 1, 2024 Category: Allergy & Immunology Authors: Deborah R. Liptzin Tags: Correspondence Source Type: research
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
CONCLUSION: Compared with FS, BF therapy appears to be a more promising treatment strategy for patients with moderate-to-severe COPD; however, this should be verified in further high-quality studies.PMID:38573085 | DOI:10.1080/15412555.2024.2328708 (Source: COPD: Journal of Chronic Obstructive Pulmonary Disease)
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - April 4, 2024 Category: Respiratory Medicine Authors: Nan Shang Yang Liu Yueping Jin Source Type: research
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study
Conclusions
In the year following treatment initiation, ICS/LABA adherence was poor and many patients discontinued or switched therapies, suggesting that more consideration and optimisation of treatment is required in England for patients initiating single-device ICS/LABA therapy. (Source: BMJ Open)
Source: BMJ Open - February 7, 2024 Category: General Medicine Authors: Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., Compton, C., Ismaila, A. Tags: Open access, Respiratory medicine Source Type: research
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials
ConclusionsThe availability of individual-level patient data in conjunction with a parametric approach enabled the characterisation of interindividual differences in the patterns of reliever use in patients with moderate-severe asthma. Taken together, individual demographic and clinical characteristics, as well as exacerbation history, can be considered an indicator of the degree of asthma control. High SABA reliever use suggests suboptimal clinical management of patients on maintenance therapy. (Source: Advances in Therapy)
Source: Advances in Therapy - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β < sub > 2 < /sub > -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis
CONCLUSION: Our findings provide important evidence on the effectiveness and safety of ICS/LABA FDC compared with LAMA for bronchiectasis. BEC/FOR and BUD/FOR were associated with better outcomes than FLU/SAL.PMID:38224017 | DOI:10.1080/17512433.2024.2306218 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - January 15, 2024 Category: Drugs & Pharmacology Authors: Vincent Yi-Fong Su Ting-Lin Ding Yuh-Lih Chang Yueh-Ching Chou Hsuen-En Hwang Chian-Ying Chou Chia-Chen Hsu Source Type: research
Therapeutic drug monitoring of corticosteroids/ β2-agonists in the hair of patients with asthma: an open-label feasibility study
Conclusion: Segmental hair analysis of inhaled medications was feasible, with low intrapatient variability. This innovative, non-invasive means of assessing monthly drug exposure might help physicians to personalize drug regimens for patients with difficult-to-treat asthma. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - January 10, 2024 Category: Drugs & Pharmacology Source Type: research
Retracted: Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
Evid Based Complement Alternat Med. 2023 Dec 13;2023:9839030. doi: 10.1155/2023/9839030. eCollection 2023.ABSTRACT[This retracts the article DOI: 10.1155/2022/8150444.].PMID:38125176 | PMC:PMC10732894 | DOI:10.1155/2023/9839030 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - December 21, 2023 Category: Complementary Medicine Authors: Evidence-Based Complementary And Alternative Medicine Source Type: research
